Format

Send to

Choose Destination
BioDrugs. 2013 Oct;27(5):431-8. doi: 10.1007/s40259-013-0040-7.

The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders.

Author information

1
Translational Immunology Section, Office of Science and Technology, National Institute of Arthritis Musculoskeletal and Skin Diseases National Institutes of Health, Bethesda, MD, 20895, USA.

Abstract

Altered production of cytokines can result in pathologies ranging from autoimmune diseases to malignancies. The Janus kinase family is a small group of receptor-associated signaling molecules that is essential to the signal cascade originating from type I and type II cytokine receptors. Inhibition of tyrosine kinase enzymatic activity using small molecules has recently become a powerful tool for treatment of several malignancies. Twenty years after the discovery of these enzymes, two inhibitors for this class of kinases have been approved for clinical use and others are currently in the final stage of development. Here we review the principles of cytokines signaling, summarize our current knowledge of the approved inhibitors, and briefly introduce some of the inhibitors that are currently under development.

PMID:
23743669
PMCID:
PMC3778139
DOI:
10.1007/s40259-013-0040-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center